When you need to know if a medication really works, why not Ask a Patient?

There is more to know than what the ads say. Learn from the experience of real people who have taken drug treatments. Share your side effects or success stories. Take control of your health by being informed and asking questions. AskaPatient.com provides tools for the empowered patient.

Recent Label Changes and FDA Safety Signals

     
  1. FETROJA:  Blood and lymphatic ...
  2. XELJANZ:  In patients with dia...
  3. ANZUPGO:  Treatment with oral ...
  4. RINVOQ:  In patients with dia...
  5. METHOTREXATE SODIUM:  Do not take Methotre...
  6. AUVELITY:  Feeling abnormal, ti...
  7. ALTACE:  Angioedema may occur...
  8. VANTAS:  Risk of Suicidal and...
  9. LUPRON:  Injection site react...
  10. LUPRON DEPOT:  Injection site react...

Poll

How much more would you be willing to pay for a safer, better quality generic drug?

Not willing to pay extra

Up to $20 extra per prescription

Different amount (list below)

Got a comment on this topic? Type your 2 cents in one sentence before voting:


Read More...

Subscribe to our free consumer-friendly health newsletter:

Medical research, new treatments, drug safety, health tips and more; delivered every other Sunday.

2026 New and Expanded Drug Approvals:

April 2026 New and Expanded Drug Approvals: For Weight Loss, Cystic Fibrosis (CF), Hunter Syndrome, Pain Pad, LAD-I, Hodgkin Lymphoma

March 2026 New and Expanded Drug Approvals: Newly approved treatments for common conditions like plaque psoriasis, obesity (the new High dose Wegovy), and liver conditions, as well as rare genetic conditions like achodroplasia.

Check out our new FDA Adverse Event Summaries:

Updated Leqembi treatment Adverse Event Monitoring System (AEMS) interactive dashboard. Covers through June 5, 2026.

Also check out our one-page summary of AEMS reports covering older drugs like: Amlodopine Besylate (Amlodopine is a commonly-used calcium channel blocker drug used to treat high blood pressure) as well as newer drugs like Cobenfy (xanomeline and trospium chloride) for schizophrenia: Cobenfy AEMS Reports Summary.